Halt Soon BUZZ is definitely undervalued. A halt can happen anytime. The FDA can approve their research to continue at any time. BUZZ has filed an application with the FDA to receive orphan drug designation for N-dimethyltryptamine (DMT). In preclinical research, DMT has been shown to improve ischemic brain damage in rats. The success of their project alone would drag the company into the multi-dollar world. And I am not talking about the legalization of their product in the world. BUZZ is a precious stone and we are fortunate to buy it for a nominal price.